[go: up one dir, main page]

AU2003289716A8 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics

Info

Publication number
AU2003289716A8
AU2003289716A8 AU2003289716A AU2003289716A AU2003289716A8 AU 2003289716 A8 AU2003289716 A8 AU 2003289716A8 AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A8 AU2003289716 A8 AU 2003289716A8
Authority
AU
Australia
Prior art keywords
therapeutics
diagnostics
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003289716A
Other versions
AU2003289716A1 (en
Inventor
Srikanth Patury
Edward J Shen
Kristian A Stevens
Darryl Gietzen
Edward S Kirton
Christina M Altus
Robert E Lagace
Xiaobing Shi
Charlyn J Suarez
Mary Kwong
Alan P Au
Martin T Suchorolski
Iqbal S Panesar
Elizabeth A Stewart
Yan Ma
Scott B Anderson
Christopher M Bruns
James Wingrove
Linda V Elder
Thirupathi P Reddy
Toinette A Harthshorne
Bonnie L Hurwitz
Careyna H Peralta
Ursula A Vitt
John L Blanchard
Rachel J Wright
Elizabeth M Mooney
Jr Edward H Gerstin
Fan Shen
Jennifer L Policky
Angelo M Delegeane
Pierre Rioux
Jennifer L Jackson
Mirjana M Marjanovic
Peter A Spiro
Yuming Xu
Xinhao Wang
Mingham C Wu
Scott R Panzer
Jeanette P Schmidt
Laura L Stuve
Steven J Pitts
Steven C Banville
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2003289716A1 publication Critical patent/AU2003289716A1/en
Publication of AU2003289716A8 publication Critical patent/AU2003289716A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2003289716A 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics Abandoned AU2003289716A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41026002P 2002-09-12 2002-09-12
US41025902P 2002-09-12 2002-09-12
US60/410,259 2002-09-12
US60/410,260 2002-09-12
PCT/US2003/028227 WO2004023973A2 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Publications (2)

Publication Number Publication Date
AU2003289716A1 AU2003289716A1 (en) 2004-04-30
AU2003289716A8 true AU2003289716A8 (en) 2004-04-30

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003289716A Abandoned AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003289716A1 (en)
WO (1) WO2004023973A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
AU2002364939A1 (en) * 2001-10-22 2003-07-09 Board Of Regents, The University Of Texas System Sperm-specific cation channel, catsper2, and uses therefor
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
WO2004053079A2 (en) 2002-12-06 2004-06-24 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2004094623A2 (en) * 2003-04-04 2004-11-04 Incyte Corporation Cell adhesion and extracellular matrix proteins
EP1630174A4 (en) * 2003-05-14 2007-06-27 Sumitomo Chemical Co ALPHA RECEPTOR LIVER MIXING PROTEIN, CORRESPONDING GENE AND USE THEREOF
WO2005019264A2 (en) * 2003-08-18 2005-03-03 Wyeth Human lxr alpha variants
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
US20070238655A1 (en) * 2003-11-12 2007-10-11 The Trustees Of The University Of Pennsylvania Methods of Using Gelsolin to Treat or Prevent Bacterial Sepsis
ATE510020T1 (en) * 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMAL WITH A POLYNUCLEOTIDE CODING FOR HUMAN-C5AR OR HUMANIZED C5AR
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
DK1755661T3 (en) 2004-05-12 2014-06-16 Brigham & Womens Hospital GELSOLIN FOR USE FOR TREATMENT OF INFECTIONS
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
EP2316927B1 (en) * 2004-10-21 2014-11-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
JP2008522632A (en) 2004-12-13 2008-07-03 アレシア・バイオセラピューティクス・インコーポレーテッド Polynucleotide and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
US20090133135A1 (en) 2005-06-01 2009-05-21 Evotec Neurosciences Gmbh Diagnostic and Therapeutic Target SLC39A11 Proteins for Neurodegenerative Diseases
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
EP3441403A1 (en) * 2005-12-20 2019-02-13 SBI Biotech Co., Ltd. Anti-ilt7 antibody
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
DK1973946T3 (en) * 2006-01-20 2015-06-22 Cell Signaling Technology Inc TRANSLOCATION AND MUTANT ROSE KINASE IN HUMAN NON-SMALL CELL LUNGCARCINOM
US20070192885A1 (en) * 2006-01-26 2007-08-16 Daniel Chelsky TAT-039 and methods of assessing and treating cancer
WO2007089783A2 (en) * 2006-01-30 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-044 and methods of assessing and treating cancer
WO2007089793A2 (en) * 2006-01-31 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-041 and methods of assessing and treating cancer
WO2007109056A2 (en) 2006-03-15 2007-09-27 The Brigham And Women's Hospital, Inc. Use of gelsolin to diagnose and treat inflammatory diseases
HUE035980T2 (en) 2006-03-15 2018-06-28 Brigham & Womens Hospital Inc Use of gelsolin to treat multiple sclerosis and to diagnose neurologic diseases
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
EP1892248A1 (en) * 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
WO2008042814A2 (en) * 2006-09-29 2008-04-10 California Institute Of Technology Mart-1 t cell receptors
JP5601836B2 (en) 2006-11-08 2014-10-08 マクロジェニックス ウエスト， インコーポレイテッド TES7 and antibodies that bind to TES7
ATE533861T1 (en) 2007-07-06 2011-12-15 Univ Michigan MIPOL1-ETV1 GENE ARRANGEMENTS
EP2185198B1 (en) 2007-08-02 2015-01-14 Gilead Biologics, Inc. Lox and l0xl2 inhibitors and uses thereof
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
JP5580205B2 (en) 2007-11-19 2014-08-27 セレラ コーポレーション Lung cancer markers and their use
AU2009203562A1 (en) * 2008-01-07 2009-07-16 Patrys Limited BARB4 target which comprises TATA-binding protein-associated factor 15, antibody designated BARB4, BARB4 related antibodies, and methods of making and using same
ES2531827T3 (en) 2008-01-25 2015-03-20 The General Hospital Corporation Therapeutic uses of gelsolin in renal failure
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
US8993728B2 (en) 2008-07-16 2015-03-31 Medical And Biological Laboratories Co., Ltd. Anti-human CLCP1 antibody and use thereof
AU2013202410B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neautralizing antibodies and use thereof
EP2328911A4 (en) * 2008-09-22 2012-03-14 Cedars Sinai Medical Center HUMAN MD-2 IN SHORT FORM AS NEGATIVE REGULATOR OF TOLL-4 TYPE RECEIVER SIGNALING
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
CA2751161C (en) * 2008-12-30 2018-10-02 Children's Medical Center Corporation Method of predicting acute appendicitis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
ES2742251T3 (en) 2009-03-16 2020-02-13 Pangu Biopharma Ltd Compositions and methods comprising variants of histidyl tarn synthetase splicing that have non-canonical biological activities
JP4495776B1 (en) * 2009-07-30 2010-07-07 日本製薬株式会社 Fusion protein
KR20120063488A (en) 2009-08-21 2012-06-15 길리아드 바이오로직스, 인크. Catalytic domains from lysyl oxidase and loxl2
WO2011034906A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
TWI507524B (en) 2009-11-30 2015-11-11 Genentech Inc Composition and method for diagnosing and treating tumor
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
CN102821784B (en) 2009-12-11 2016-09-21 Atyr医药公司 Aminoacyl tRNA synthetases for regulation of inflammation
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
AU2011248357B2 (en) * 2010-05-03 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
CN103108649B (en) 2010-07-12 2016-10-12 Atyr医药公司 Treatment, diagnosis and the antibody compositions relevant to the protein fragments of Jo-1
CA2808539C (en) 2010-08-25 2021-05-25 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-trna synthetases
WO2012042038A2 (en) * 2010-09-30 2012-04-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
CA2852629A1 (en) * 2011-10-26 2013-05-02 Nuclea Biotechnologies, Inc. Usp2a peptides and antibodies
DK2814514T3 (en) 2012-02-16 2017-12-18 Atyr Pharma Inc Histidyl tRNA synthetases for the treatment of autoimmune and inflammatory diseases
CN104271593B (en) * 2012-05-01 2018-01-16 富士胶片株式会社 The polypeptide used in the cultural method and this method of multipotential stem cell
JP6449772B2 (en) * 2012-10-05 2019-01-09 カドモン コーポレイション，リミティド ライアビリティ カンパニー Human anti-VEGFR2 / KDR antibody
HK1215261A1 (en) 2013-03-14 2016-08-19 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta complexed with heparin
ES2847383T3 (en) 2013-03-15 2021-08-03 Atyr Pharma Inc Fc-histidyl-tRNA synthetase conjugates
EP4060344A1 (en) 2015-06-08 2022-09-21 Arquer Diagnostics Limited Methods and kits
WO2016198833A2 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods
WO2017024137A1 (en) * 2015-08-04 2017-02-09 New York University Progranulin (pgrn) fragments and derivatives for treatment or alleviation of lysosomal storage diseases
EP3426298A4 (en) 2016-03-10 2019-11-27 Viela Bio, Inc. ILT7 BINDING MOLECULES AND METHODS OF USE
US11505590B2 (en) 2016-04-08 2022-11-22 Immunocore Limited T cell receptors
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
EP3612215B1 (en) 2017-04-20 2024-08-28 aTyr Pharma, Inc. Compositions for treating lung inflammation
SG11201910101SA (en) 2017-05-08 2019-11-28 Gritstone Oncology Inc Alphavirus neoantigen vectors
EP3635009A1 (en) 2017-06-07 2020-04-15 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
TWI820034B (en) * 2017-07-31 2023-11-01 香港商映像生物有限公司 Cellular models of and therapies for ocular diseases
KR20200118029A (en) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 Anti-tissue factor antibodies, antibody-drug conjugates, and related methods
IL322464A (en) 2018-02-07 2025-09-01 Regeneron Pharma Methods and compositions for therapeutic protein delivery
GB201803010D0 (en) 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
AU2019256383A1 (en) 2018-04-17 2020-11-26 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
EP3793591A1 (en) 2018-05-17 2021-03-24 Regeneron Pharmaceuticals, Inc. Anti-cd63 antibodies, conjugates, and uses thereof
CN114072516B (en) 2019-05-30 2025-01-14 磨石生物公司 Modified adenovirus
CN111859913B (en) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 Processing method and device of wind control characteristic factors, electronic equipment and storage medium
JP2023541108A (en) 2020-08-06 2023-09-28 グリットストーン バイオ インコーポレイテッド Multi-epitope vaccine cassette
EP4313113A4 (en) * 2021-03-30 2025-04-16 Board of Regents, The University of Texas System CITRULLINATED PROTEINS AS BIOMARKERS AND THERAPEUTIC TARGETS FOR CANCER
IL319060A (en) 2022-08-18 2025-04-01 Immunocore Ltd T cell receptor fusion proteins specific for mage a4
WO2024163607A2 (en) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting egfr and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001053531A2 (en) * 2000-01-18 2001-07-26 Pharmacia Corporation Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Also Published As

Publication number Publication date
WO2004023973A2 (en) 2004-03-25
AU2003289716A1 (en) 2004-04-30
WO2004023973A3 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
AU2003289716A8 (en) Molecules for diagnostics and therapeutics
AU2002344208A8 (en) Molecules for diagnostics and therapeutics
EP1552002A4 (en) Aptamer-toxin molecules and methods for using same
EP1644572A4 (en) Fabric-faced composites and methods for making same
IL175491A0 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
GB0301227D0 (en) Seating apparatus
AU2003278578A8 (en) Molecules and methods using same for measuring non-transferrin bound iron
GB0417263D0 (en) Process and system
GB0306657D0 (en) Process and compounds
AU2003210518A1 (en) Molecules for diagnostics and therapeutics
ZA200600473B (en) Salinosporamides and methods for use thereof
GB0328314D0 (en) Therapeutics
GB0317393D0 (en) Process and compounds
GB0321086D0 (en) Buses
GB2401864B (en) Process and catalytic composition
EP1676853A4 (en) Alpha-1-phosphorylated-2-deoxy-2-fluoroarabinoside and process for producing 2 -deoxy-2 -fluoro-beta-d-arabinonucleosid e
AU2002305913A1 (en) Molecules for diagnostics and therapeutics
GB0209040D0 (en) Improvements in diagnostics
AU4175401A (en) Molecules for diagnostics and therapeutics
AU8696401A (en) Molecules for diagnostics and therapeutics
AU2003231740A8 (en) Compositions and methods for diagnostics and therapeutics for hydrocephalus
GB0306185D0 (en) Molecules
GB0227026D0 (en) Psoriasis diagnostics and therapeutics
HU0304025D0 (en) New process and new intermediate
GB0209619D0 (en) Molecules

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase